China's ZAI Lab Ltd. has decided to return its rights to Hanmi Pharmaceutical Co. Ltd.'s novel third-generation epidermal growth factor receptor (EGFR), mutation-specific tyrosine kinase inhibitor (TKI) olmutinib (HM61713), due to a change in its new drug development strategy, said the leading South Korean pharma firm.
Hanmi Mulls New Trial Strategy As ZAI Lab Ends Olmutinib Partnership
Hanmi is reviewing a new global clinical trial plan for its novel lung cancer drug olmutinib after China's ZAI Lab returned its rights, and following Boehringer’s cancellation of a major-licensing deal in 2016. ZAI's decision may reflect the difficulties faced by olmutinib and other third generation EGFR inhibitors in competing with Tagrisso, as well as the increasingly crowded and rapidly changing non-small cell lung cancer space.
More from Business
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.
• By
CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
More from Scrip
• By
CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.